|
|
Article: Bio-Matrix Scientific Group's Subsidiary Applies for Phase II Grant from National Cancer Institute for the Development of Immuno-Therapeutic Cancer Vaccine.
- Article from:
- Cancer Vaccine Week
- Article date:
- October 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Entest BioMedical, Inc. (OTCBB: ENTB) a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI) (see also Bio-Matrix Scientific Group, Inc.).
David Koos, Chairman and CEO of Bio-Matrix Scientific Group and its majority owned subsidiary, Entest BioMedical, Inc. says, "Our goal with this research is to test a viable and groundbreaking cancer treatment, first in the veterinary oncology market and then, if successful, to move on to human clinical trials."
The Entest application involves perfecting the use of cell lines for ...